£138 million boost for vaccine development in the UK

18 May 2020
lab_biotech_research_vaccine_big

An investment of £138 million ($167 million) from the UK government will help boost vaccines manufacturing capacity, as well as establish a “virtual VMIC” in the country.

The investment is being made in the Vaccines Manufacturing and Innovation Centre (VMIC), a not-for-profit organization providing strategic vaccine development and advanced manufacturing capability.

The group, which is based at the Harwell campus, just outside Oxford, will receive £93 million to rapidly expand the facility's capabilities.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology